Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.54 |
| ▸ | NPY4R | P50391 | 6/20 | 0.53 |
| ▸ | NPY1R | P25929 | 5/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880895 | 0.92 | OPRM1 (0.60) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL31688341 | 0.91 | TFPI (0.64) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL30553847 | 0.89 | TFPI (0.58) | OPRM1OPRD1OPRK1TFPIKISS1R | |
| SCHEMBL30184205 | 0.89 | OPRM1 (0.61) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL30578725 | 0.88 | OPRM1 (0.58) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL31232489 | 0.87 | OPRM1 (0.65) | OPRM1OPRD1OPRK1KISS1RNPY4R | |
| SCHEMBL29412269 | 0.87 | NPY4R (0.60) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL30819888 | 0.86 | OPRM1 (0.57) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL30317558 | 0.86 | TFPI (0.54) | OPRM1OPRD1OPRK1TFPIIL23R | |
| SCHEMBL30101010 | 0.86 | NPY4R (0.63) | OPRM1OPRD1OPRK1TFPINPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | OPRM1 4474/4885OPRD1 3916/4885OPRK1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.